[Modification of some prothrombotic indices after treatment with iloprost in arterial disease patients].
The authors analyse the short-term and medium-term effects of iloprost prostanoid derivate on hemostatic status in a group of patients with obliterating vascular disease of the lower limbs. The study included 10 patients (6 males, 4 females; aged 52 + 5 years old) suffering from Fontaine's stage 3 obstructive arterial disease. After a 10-hour fast each patient received a 6-hour iv infusion of iloprost at a dose of 2 ng/kg/min (approx 50 gamma) a venous blood sample was collected before and after infusion. The test was repeated using the same method after 4 weeks of treatment with the same dose of the drug. The following parameters were analysed in serum: fibrinogen (F) (IL coagulometric method), Factor VII (F VII) (IL coagulometric method), antithrombin II (AT III) (IL chromogenic method), protein C (PC) II coagulometric method) and protein S (PS) (IL coagulometric method). After the first infusion a significant increase was observed in AT III (p > 0.05), whereas other indices showed no significant variations. After treatment for 4 weeks AT III was again enhanced after infusion (p > 0.05); with regard to the basal values of other parameters, a significant reduction (p > 0.05) was found in F VII, whereas no other significant changes were observed. In the light of these results the authors suggest an antithrombotic effect of the drug documented by the short-term increase in AT III probably due to lower consumption, and a medium-term reduction in F VII due to trophic effect of the drug at a vasculoparietal level resulting in the depression of FVII tissue activation factors.
Ferlito
S
S
Cattedra di Semeiotica e Metodologia Medica, Università degli Studi, Catania.
Bonomo
T
T
Costa
R
R
Di Salvo
M M
MM
Attanasio
L
L
Finocchiaro
P M
PM
Condorelli
M
M
Mazzone
D
D
D001157:Arterial Occlusive Diseases / Q000097:blood* / Q000188:drug therapy; D001779:Blood Coagulation Factors / Q000187:drug effects*; D005260:Female; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D010975:Platelet Aggregation Inhibitors; D016285:Iloprost
Modificazioni di alcuni indici protrombotici dopo trattamento con iloprost in arteriopatici.